Figure 3From: Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trialMedian change in bone mineral density (BMD) of lumbar spine (LS) (a) and hip (HP) (b). Error bars indicate interquartile range. A, anastrozole; R, risedronate (randomized arms only).Back to article page